Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Accounts Payables (2016 - 2025)

VYNE Therapeutics' Accounts Payables history spans 10 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 61.54% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, down 61.54%, while the annual FY2025 figure was $1.0 million, 61.54% down from the prior year.
  • Accounts Payables reached $1.0 million in Q4 2025 per VYNE's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $10.1 million in Q2 2021 to a low of $716000.0 in Q3 2023.
  • Average Accounts Payables over 5 years is $3.3 million, with a median of $2.7 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: crashed 85.8% in 2022, then soared 456.7% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $6.5 million in 2021, then plummeted by 63.35% to $2.4 million in 2022, then tumbled by 30.47% to $1.7 million in 2023, then soared by 63.17% to $2.7 million in 2024, then tumbled by 61.54% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Accounts Payables are $1.0 million (Q4 2025), $1.4 million (Q2 2025), and $3.5 million (Q1 2025).